Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage
Ended Project Grant Awarded Last action
- Award ID
- R41NS122656
- Recipient
-
Vasametrix LLC UEI JM3XTRKT11T6
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $523,726
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Place of performance
- Nashville, TN 37212, USA
Award details come from USAspending.gov.
Description
- Abstract
- Subarachnoid hemorrhage (SAH) due to rupture of an intracranial aneurysm leads to delayed vasospasm resulting in neuroischemia (stroke). The overall morbidity (profound neurologic deficit in 10-20% of survivors) and mortality (50%) are high, and the disease affects a relatively young adult population. Therapeutic options to prevent delayed vasospasm and neuroischemia after SAH are currently limited to hemodynamic optimization and nimodipine, which have marginal clinical efficacy. Thus, treatment of delayed vasospasm after SAH represents an unmet clinical need in an orphan population with severe clinical consequences. Attempts to treat SAH-induced vasospasm with existing vasodilators often fail because of systemic hypotension (leading to decreased cerebral perfusion) and a cerebral vasculature that is refractory to activation of nitric oxide (no)-dependent signaling pathways.5 no signaling modulates vascular smooth muscle (VSM) relaxation and regulation of cerebral blood flow. The impaired response of cerebral vessels to vasodilators, i.e. impaired vasorelaxation after SAH, is likely due to down regulation of the signaling elements in the no pathway after SAH. The hypothesis of this investigation is that treatment with a rationally designed, cell permeant phosphopeptide mimetic of a downstream effector protein of the no pathway will bypass downregulated signaling elements, restore vasorelaxation, and prevent delayed vasospasm after SAH. This approach is more targeted and stoichiometric than approaches that activate or inhibit receptors or enzymes. In addition, this approach is particularly useful in SAH where preventing systemic hypotension and optimizing cerebral vasodilation is paramount. A family of cell permeant phosphopeptide analogues of a substrate of cgmp-dependent protein kinase (PKG), and an actin-associated protein that modulates VSM relaxation, were rationally designed and synthesized. Three candidate peptides were demonstrated to directly relax intact VSM in EX vivo bioactivity assays. The peptide with the shortest sequence (denoted as VP3) and strongest bioactivity was chosen as the optimal peptide for use to determine in vivo efficacy.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $261,863 | |
| Original award | $261,863 |
Quick answers
Who received award R41NS122656?
R41NS122656 was awarded to Vasametrix LLC by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on February 1, 2022.
How much is award R41NS122656 worth?
$523,726 has been obligated on R41NS122656.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award